Shopping Cart
- Remove All
Your shopping cart is currently empty
CU-CPT22
🥰Excellent
Catalog No. T15020Cas No. 1416324-85-0
CU-CPT22 is the first probe for the complex between toll-like receptors TLR1 and TLR2. CU-CPT22 binds at the interface of TLR1 and TLR2 (IC50 = 0.58 μM). It competes with the synthetic triacylated lipoprotein (Pam3CSK4) binding to TLR1/2 (Ki: 0.41 μM).
CU-CPT22
🥰Excellent
Purity: 98.66%
Catalog No. T15020Cas No. 1416324-85-0
CU-CPT22 is the first probe for the complex between toll-like receptors TLR1 and TLR2. CU-CPT22 binds at the interface of TLR1 and TLR2 (IC50 = 0.58 μM). It competes with the synthetic triacylated lipoprotein (Pam3CSK4) binding to TLR1/2 (Ki: 0.41 μM).
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $44 | In Stock | |
| 2 mg | $64 | In Stock | |
| 5 mg | $101 | In Stock | |
| 10 mg | $171 | In Stock | |
| 25 mg | $329 | In Stock | |
| 50 mg | $493 | In Stock | |
| 100 mg | $718 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $116 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "CU-CPT22"
Hydroxychloroquine
Cited
2-[[4-[(7-Chloroquinolin-4-yl)amino]pentyl](ethyl)amino]ethanol
T9287118-42-3
Hydroxychloroquine (2-[[4-[(7-Chloroquinolin-4-yl)amino]pentyl](ethyl)amino]ethanol) (HCQ) is an alkalinizing lysosomatropic drug that acts by inducing apoptosis of renal cancer cells in vitro and inhibiting TLR7/9. It is a medication used to prevent and treat malaria, and it's also being studied as an experimental treatment for COVID-19.
- $30
Size
QTY
CitedChloranil
p-Chloranil
T80673118-75-2
Chloranil (tetrachloro-p-benzoquinone) triggers inflammation and neurological dysfunction through Toll-like receptor 4 signaling and can be used to model inflammation in mice.
- $29
Size
QTY
Chloroquine phosphate Cited
Chloroquine diphosphate, Chingamin phosphate, Aralen phosphate
T019450-63-5
Chloroquine phosphate (Aralen phosphate) is an aminoquinoline antimalarial and also is widely used as an autophagy inhibitor. Chloroquine also is an inhibitor of toll-like receptors (TLRs).
- $42
Size
QTY
CitedChloroquine
Cited
CQ
T868954-05-7
Chloroquine is a Toll-like receptor inhibitor that inhibits autophagy. Chloroquine has anti-malarial and anti-inflammatory activity and is widely used in the treatment of malaria and rheumatoid arthritis. Chloroquine also has anti-SARS-CoV-2 (COVID-19) activity and anti-HIV-1 activity.
- $54
Size
QTY
CitedResiquimod Cited
S28463, R848
T6964144875-48-9
Resiquimod (R848) is a Toll-like receptor 7/8 (TLR7/TLR8) agonist that induces cytokine upregulation. Resiquimod is an immunomodulator with antitumor and antiviral activity.
- $30
Size
QTY
CitedImiquimod Cited
S-26308, R 837, IMQ
T013499011-02-6
Imiquimod (R 837) is an immune response modifier that acts as a toll-like receptor 7 agonist.
- $37
Size
QTY
CitedCU-115
N-(4-(3,5-bis(trifluoromethyl)phenoxy)phenyl)-2-fluoro-6-iodobenzamide
T96452471982-20-2In house
CU-115 is a selective and potent TLR8 antagonist with IC50 of 1.04 µM and =>50 µM for TLR8 and TLR7, respectively. CU-115 decreases production of TNF-α and IL-1β activated by R-848 in THP-1 cells.
- $53
Size
QTY
TLR3-IN-1
CU CPT 4a
T226981279713-77-7
TLR3-IN-1 (CU CPT 4a) is a selective TLR3 inhibitor (IC50: 3.44 μM in RAW 264.7 cells). It can inhibit TLR3/dsRNA complex-mediated downstream signaling pathways and inhibit the production of TNF-α and IL-1β in whole cells.
- $48
Size
QTY
RV01
T127811016897-10-1
RV01 is a novel quinoline-substituted analogue of resveratrol that inhibits DNA damage, reduces ethanol-induced acetaldehyde dehydrogenase (ALDH2) mRNA expression, and has hydroxyl radical scavenging activity. rV01 reduces iNOS expression and has anti-neuroinflammatory effects. rV01 reduces tumor necrosis factor-a (TNF-a) and interleukin-6 (IL-6) mRNA levels and secretion. RV01 reduced tumor necrosis factor-a (TNF-a) and interleukin-6 (IL-6) mRNA levels and secretion, inhibited lps-induced ROS production and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activation, decreased toll-like receptor 4 (TLR4) protein expression, and inhibited lps-induced activation of mitogen-activated protein kinase (MAPK) and nuclear transcription factor-кB (NF-кB) signaling pathways.
- $56
Size
QTY
Hydroxychloroquine sulfate Cited
HCQ sulfate, Acidum iopanoicum
T0951747-36-4
Hydroxychloroquine sulfate (Acidum iopanoicum) inhibits plasmodial heme polymerase. It is a chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa.
- $48
Size
QTY
CitedPolyinosinic-polycytidylic acid sodium
Poly(I:C) sodium
T1251642424-50-0
Polyinosinic-polycytidylic acid sodium (Poly(I:C) sodium) is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5).
- $38
Size
QTY
CU-CPD107
CU-CPD107
T353492573912-32-8In house
CU-CPD107 is a selective agonist of toll-like receptor 8 (TLR8) and also shows activation activity against ssRNA ligands. CU-CPD107 acts as an inhibitor of TLR8 signaling in the presence of R848 (IC50=13.7 μM). CU-CPD107 exhibited coagonist activity in the presence of ssRNA, while CU-CPD107 alone could not affect TLR8 signal transduction.
- $60
Size
QTY
Select Batch
Purity:98.66%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | CU-CPT22 is the first probe for the complex between toll-like receptors TLR1 and TLR2. CU-CPT22 binds at the interface of TLR1 and TLR2 (IC50 = 0.58 μM). It competes with the synthetic triacylated lipoprotein (Pam3CSK4) binding to TLR1/2 (Ki: 0.41 μM). |
| Targets&IC50 | TLR2/1:(ki)0.41 μM |
| In vitro | A novel compound (CU-CPT22) that can compete with the synthetic triacylated lipoprotein (Pam3CSK4) binding to TLR1/2 with high inhibitory activity and specificity.CU-CPT22 is a toll-like inhibitor of receptor 1 and 2 (TLR1/2) ( IC50: 0.58±0.09 μM).?CU-CPT22 is found to have no significant cytotoxicity at various concentrations up to 100 μM in RAW 264.7 cells.?It is showed that CU-CPT22 is able to compete with Pam3CSK4 for binding to TLR1/2 (Ki: 0.41±0.07 μM).?Which is consistent with its potency observed in the whole cell assay.?Increasing the concentration of CU-CPT22 to 6 μM decreases the anisotropy to background levels.?It is found that CU-CPT22 inhibits TLR1/2 signaling without affecting other TLRs, showing it is highly selective in intact cells.??The result shows that CU-CPT22 can inhibit about 60% of TNF-αand 95% of IL-1β at 8 μM[1]. |
| Molecular Weight | 362.37 |
| Formula | C19H22O7 |
| Cas No. | 1416324-85-0 |
| Smiles | CCCCCCOC(=O)c1cc(O)c(=O)c2c(O)c(O)c(OC)cc2c1 |
| Relative Density. | 1.336 g/cm3 (Predicted) |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 125 mg/mL (344.95 mM) | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy CU-CPT22 | purchase CU-CPT22 | CU-CPT22 cost | order CU-CPT22 | CU-CPT22 chemical structure | CU-CPT22 in vitro | CU-CPT22 formula | CU-CPT22 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.